上海出台18条措施促生物医药创新

Core Points - Shanghai has introduced measures to promote the high-quality development of commercial health insurance, aimed at supporting innovation in the biopharmaceutical industry and enhancing public health insurance services [1] - The measures include 5 areas and 18 specific actions to improve the accessibility and affordability of innovative drugs and medical devices, addressing the diverse health protection needs of citizens [1] Summary by Categories Policy Measures - The measures focus on deepening the payment mechanism for innovative drugs and medical devices, facilitating their entry into hospitals, directories, and prescriptions [1] - Cases involving innovative drugs within the scope of commercial health insurance will not be included in the disease-based payment range, encouraging insurance companies to use clinical trial data for pricing [1] Technological Integration - Shanghai will enhance the functionality of the "Shanghai Insurance Code" to optimize the synchronous settlement model between public health insurance and commercial insurance [1] - The initiative aims to improve direct compensation service processes and establish an active compensation system that integrates medical, health insurance, and commercial insurance data [1] Impact on Health Insurance - The introduction of these measures is expected to further establish commercial health insurance as a crucial pillar of the public health protection system, providing citizens with more comprehensive, diverse, and convenient health coverage [1]